RevMed RMC-6236-001: A Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Mutations in KRAS at Position G12.

Brief description of study

This study is testing a new medicine, RMC-6236, for patients with certain advanced cancers that have specific changes in a gene called RAS. RMC-6236 aims to stop the growth of cancer cells. This study has two parts. In the first part, the study team will figure out the most effective amount of the medicine with the least amount of side effects by testing different doses of the medicine. In the second part, more patients will get the chosen dose to see if it works well for specific types of cancer like lung, pancreatic, and colorectal cancers. The study team will also check if taking the medicine with or without food makes a difference. The goal is to find a better treatment for these specific cancers, as current treatments often don't work well. The study team will closely watch patients for safety, and it aims to see if RMC-6236 could be a helpful option for these types of cancers.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.